# A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

> **NCT06207877** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 62 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06207877
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-23
- **Primary completion:** 2024-10-16
- **Final completion:** 2024-11-22
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06207877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06207877, "A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06207877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*